864277-04-3

Basic information

• Product Name: 1-(5-ethoxycarbonylthiazol-2-yl)-4-(4-iodophenylsulfonyl)piperazine
• Synonyms: 1-(5-ethoxycarbonylthiazol-2-yl)-4-(4-iodophenylsulfonyl)piperazine
• CAS NO: 864277-04-3
• Molecular Weight: 507.373
• Mol File: 864277-04-3.mol

Chemical Properties

• CAS DataBase Reference: 1-(5-ethoxycarbonylthiazol-2-yl)-4-(4-iodophenylsulfonyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-ethoxycarbonylthiazol-2-yl)-4-(4-iodophenylsulfonyl)piperazine(864277-04-3)
• EPA Substance Registry System: 1-(5-ethoxycarbonylthiazol-2-yl)-4-(4-iodophenylsulfonyl)piperazine(864277-04-3)

Safety Data

• Hazardous Substances Data: 864277-04-3(Hazardous Substances Data)

Upstream product

• 873075-57-1 ethyl 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)thiazole-5-carboxylate 
• 98-61-3 p-Iodobenzenesulfonyl chloride 
• 41731-83-3 ethyl 2-bromo-1,3-thiazole-5-carboxylate 
• 864277-03-2 2-piperazin-1-yl-thiazol-5-carboxylic acid ethyl ester 

Downstream Products

• 864277-05-4 C₂₂H₂₂FN₃O₄S₂ 
• 864277-08-7 N-(3’-(piperidin-1-ylmethyl)-[1,1’-biphenyl]-4-yl)sulfonyl-N’-(5-ethoxycarbonylthiazol-2-yl)piperazine 

Relevant articles and documents

Synthesis of Biaryls Having a Piperidylmethyl Group Based on Space Integration of Lithiation, Borylation, and Suzuki–Miyaura Coupling

In a flow microreactor, aryllithiums bearing a piperidylmethyl group were generated using nBuLi by precise residence time control and effective temperature control, and then selectively borylated with boronic esters such as 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (BpinOiPr) and trimethyl borate B(OMe)3 by fast mixing. Moreover, the direct integration with Suzuki–Miyaura cross coupling were successfully achieved to obtain nitrogen-containing biaryl compounds. The present method could be applied for the straightforward synthesis of the key intermediate of a bioactive component bearing a piperidylmethyl-biphenyl framework.

Inhibitors of histone deacetylase

Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least